• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Dermatology

Pembrolizumab for the treatment of advanced melanoma

byAdarsh ManjunathandMichael Milligan
April 21, 2016
in Dermatology, Oncology
Reading Time: 2 mins read
Women with pregnancy-associated melanoma at greater risk of metastasis, recurrence
Share on FacebookShare on TwitterShare on LinkedIn

1. For patients with unresectable melanoma or metastatic melanoma that progressed despite treatment, pembrolizumab treatment resulted in objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months.

2. Pembrolizumab administration was associated with a 14% rate of grade 3 or 4 treatment-related adverse events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Pembrolizumab is a monoclonal antibody that blocks the programmed death-1 pathway, and is used for unresectable melanoma or metastatic melanoma that has progressed after first line treatments. The purpose of this study was to determine the effects of pembrolizumab in terms of antitumor activity and overall survival in patients with advanced melanoma. In an open-label, multi-cohort study across academic medical centers in four countries, data was pooled from 655 enrolled patients and 520 patients from randomized cohorts. Objective responses were reported in 33% of patients with measurable disease and in 45% of patients who were treatment-naïve. Twelve-month progression-free survival rates were 35% in the total population and 52% in treatment-naïve patients. Median overall survival in the total population was 23 months compared to 31 months in the treatment-naïve group. About 14% of patients had 1 treatment-related grade 3 or 4 adverse event, and 9% of patients had a treatment-related serious adverse effect, with no drug-related deaths.

Overall, this study presents response rates and survival rates with pembrolizumab administration. It benefited from having patients enrolled at numerous centers around the world and having a follow-up of 21 months. Further studies are needed to compare pembrolizumab to current standard of care therapies.

Click to read the study in JAMA (Journal of the American Medical Association)

RELATED REPORTS

Less social media usage is associated with improved internalizing symptoms in high-risk young adults.

AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality

Relevant Reading: The blockade of immune checkpoints in cancer immunotherapy.

FDA approvedFor melanoma: Tudriqev (vusolimogene oderparepvec-wtpg), Aug 6, 2026→

In-Depth [randomized controlled trial]: This open-label, multi-cohort clinical trial looked to determine the tumor response rates and the overall survival among patients with advanced melanoma treated with pembrolizumab. Specifically, data was pooled from 655 enrolled patients and 520 patients from randomized cohorts from academic medical centers in four countries. Patients had to have unresectable melanoma or metastatic melanoma that had progressed after first-line treatments. Objective responses were reported in 33% (95%CI 30-37%) of patients with measurable disease and in 45% (95%CI 36-54%) of patients who were treatment-naïve. Twelve-month progression-free survival rates were 35% (95%CI 31-39%) in the total population and 52% (95%CI 43-60%) in treatment-naïve patients. Median overall survival in the total population was 23 months (95%CI 20-29 months) compared to 31 months (95%CI 24-not reached) in the treatment-naïve group. Approximately 14% of patients had 1 treatment-related grade 3 or 4 adverse event, and 9% of patients had a treatment-related serious adverse effect, with no drug-related deaths.

 

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Anticholinergic medications linked to worsened cognition, brain metabolism, and atrophy

Next Post

ACE inhibitors alone equally effective, safer versus combination regimen for heart failure patients

RelatedReports

Teen smartphone use collage: a teenage boy in a hoodie looking down at a phone, with empty speech bubbles rising from it
All Specialties

Less social media usage is associated with improved internalizing symptoms in high-risk young adults.

November 19, 2026
Physical activity collage: an engraved bicycle, a water bottle lying on its side and a path of flat stepping stones
Artificial Intelligence

AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality

November 19, 2026
An abstract representation featuring a syringe, pills, a silhouette of a person, and molecular structures, suggesting themes related to obesity treatment.
All Specialties

In a phase 3 trial, tirzepatide reduced BMI versus placebo in adolescents with obesity and obesity-related complications

November 19, 2026
Lung cancer immunotherapy collage: engraved lungs and trachea, a cluster of round immune cells and a folded surgical towel
Cardiology

Continuation of immunotherapy after immune checkpoint inhibitor-induced myocarditis in patients with lung cancer may be safe and effective

November 19, 2026
Next Post
ACE inhibitors alone equally effective, safer versus combination regimen for heart failure patients

ACE inhibitors alone equally effective, safer versus combination regimen for heart failure patients

TIAregistry.org provides modern update to etiologies and outcomes in TIA

BRCA1 mutation linked to lower AMH levels

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
  • In a phase 3 trial, tirzepatide reduced BMI versus placebo in adolescents with obesity and obesity-related complications
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.